DK0975771T3 - Fusionsproteiner af TGF-beta-receptortype II og immunoglobulins konstante region - Google Patents

Fusionsproteiner af TGF-beta-receptortype II og immunoglobulins konstante region

Info

Publication number
DK0975771T3
DK0975771T3 DK98918247T DK98918247T DK0975771T3 DK 0975771 T3 DK0975771 T3 DK 0975771T3 DK 98918247 T DK98918247 T DK 98918247T DK 98918247 T DK98918247 T DK 98918247T DK 0975771 T3 DK0975771 T3 DK 0975771T3
Authority
DK
Denmark
Prior art keywords
fusion proteins
tgf
immunoglobulin constant
constant region
receptor type
Prior art date
Application number
DK98918247T
Other languages
English (en)
Inventor
Philip Gotwals
Victor Koteliansky
Richard Cate
Michelle Sanicola-Nadel
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Application granted granted Critical
Publication of DK0975771T3 publication Critical patent/DK0975771T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
DK98918247T 1997-04-18 1998-04-16 Fusionsproteiner af TGF-beta-receptortype II og immunoglobulins konstante region DK0975771T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4464197P 1997-04-18 1997-04-18
PCT/US1998/007587 WO1998048024A1 (en) 1997-04-18 1998-04-16 Type ii tgf-beta receptor/immunoglobulin constant region fusion proteins

Publications (1)

Publication Number Publication Date
DK0975771T3 true DK0975771T3 (da) 2007-10-22

Family

ID=21933495

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98918247T DK0975771T3 (da) 1997-04-18 1998-04-16 Fusionsproteiner af TGF-beta-receptortype II og immunoglobulins konstante region

Country Status (22)

Country Link
US (1) US20050203022A1 (da)
EP (1) EP0975771B1 (da)
JP (2) JP2001515360A (da)
KR (1) KR20010006534A (da)
CN (1) CN1257545A (da)
AT (1) ATE366816T1 (da)
AU (1) AU737106B2 (da)
BR (1) BR9808934A (da)
CA (1) CA2286933A1 (da)
DE (1) DE69838061T2 (da)
DK (1) DK0975771T3 (da)
EA (1) EA199900947A1 (da)
EE (1) EE9900492A (da)
ES (1) ES2289778T3 (da)
IL (1) IL132249A0 (da)
IS (1) IS5217A (da)
NO (1) NO994998L (da)
NZ (1) NZ500284A (da)
PL (1) PL336306A1 (da)
PT (1) PT975771E (da)
TR (1) TR199902878T2 (da)
WO (1) WO1998048024A1 (da)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6740506B2 (en) 1995-12-07 2004-05-25 Diversa Corporation End selection in directed evolution
US6358709B1 (en) 1995-12-07 2002-03-19 Diversa Corporation End selection in directed evolution
US6939689B2 (en) 1995-12-07 2005-09-06 Diversa Corporation Exonuclease-mediated nucleic acid reassembly in directed evolution
US6238884B1 (en) 1995-12-07 2001-05-29 Diversa Corporation End selection in directed evolution
US6562594B1 (en) 1999-09-29 2003-05-13 Diversa Corporation Saturation mutagenesis in directed evolution
US6361974B1 (en) 1995-12-07 2002-03-26 Diversa Corporation Exonuclease-mediated nucleic acid reassembly in directed evolution
US6537776B1 (en) 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
US7018793B1 (en) 1995-12-07 2006-03-28 Diversa Corporation Combinatorial screening of mixed populations of organisms
US6713279B1 (en) 1995-12-07 2004-03-30 Diversa Corporation Non-stochastic generation of genetic vaccines and enzymes
US5830696A (en) 1996-12-05 1998-11-03 Diversa Corporation Directed evolution of thermophilic enzymes
US6352842B1 (en) 1995-12-07 2002-03-05 Diversa Corporation Exonucease-mediated gene assembly in directed evolution
US6171820B1 (en) 1995-12-07 2001-01-09 Diversa Corporation Saturation mutagenesis in directed evolution
US6492325B1 (en) 1998-05-22 2002-12-10 Boys Town National Research Hospital Use of α1β1 integrin receptor inhibitors and TGF-β1 inhibitors in the treatment of kidney disease
AU4572899A (en) * 1998-06-16 2000-01-05 Biogen, Inc. Variant type ii tgf-beta receptor fusion proteins and methods
DE1221490T1 (de) 1999-09-17 2003-05-28 Tgt Lab S A De C V Rekombinante, adenovirale vektoren und ihre verwendung zur behandlung von unterschiedlichen typen der leber-, nieren- und lungenfibrose und hypertrophischen narben
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
MXPA00011713A (es) * 2000-11-28 2002-05-31 Tgt Lab S A De C V Vectores recombinantes virales y no virales conteniendo el gen humano del activador de plasminogeno derivado de urocinasa y su utilidad en el tratamiento de diversos tipos de fibrosis hepatica, renal, pulmonar, pancreatica, cardiaca y cicatrices hipe
DK2116259T3 (da) * 2001-05-24 2012-05-21 Zymogenetics Inc TACI-immunoglobulinfusionsproteiner
ES2526705T3 (es) 2005-10-25 2015-01-14 The Johns Hopkins University Métodos y composiciones para el tratamiento de síndrome de Marfan y trastornos asociados
WO2007108992A2 (en) 2006-03-13 2007-09-27 The Johns Hopkins University Augmentation of endothelial thromboresistance
US20100098668A1 (en) * 2006-09-29 2010-04-22 Northshore University Health System Oncolytic Adenoviruses and Uses Thereof
EP2918288B1 (en) 2006-10-03 2017-08-16 Genzyme Corporation Use of TGF beta antagonists to treat infants at risk of developing bronchopulmonary dysplasia
WO2008157367A1 (en) * 2007-06-15 2008-12-24 Genzyme Corporation Fusion proteins containing two tgf-beta binding domains of tgf-beta type ii receptor
WO2009152610A1 (en) 2008-06-20 2009-12-23 The Royal Institution For The Advancement Of Learning/Mcgill University Interleukin-2/soluble tgf-beta type ii receptor b conjugates and methods and uses thereof
WO2011100460A2 (en) * 2010-02-11 2011-08-18 Ecole Polytechnique Federale De Lausanne Ccr7 ligand delivery and co-delivery in immunotherapy
JP6017422B2 (ja) 2010-08-10 2016-11-02 エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ（ウペエフエル）Ｅｃｏｌｅ Ｐｏｌｙｔｅｃｈｎｉｑｕｅ Ｆｅｄｅｒａｌｅ ｄｅ Ｌａｕｓａｎｎｅ （ＥＰＦＬ） 赤血球結合療法
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
CA2823154A1 (en) 2010-12-27 2012-07-05 Lsip, Llc Ips cells and method for generating same
CN102175501A (zh) * 2011-01-07 2011-09-07 山东省农业科学院作物研究所 用于显微镜观察的植物样品的前处理方法
EP2737083A1 (en) 2011-07-27 2014-06-04 INSERM (Institut National de la Santé et de la Recherche Scientifique) Methods for diagnosing and treating myhre syndrome
CN102898508B (zh) * 2011-08-12 2014-04-30 北京大学第一医院 封闭TGF-β受体或IL-10受体的多肽、其药物组合物及其用途
WO2013062544A1 (en) 2011-10-26 2013-05-02 Seattle Children's Research Institute Cysteamine in the treatment of fibrotic disease
ES2917222T3 (es) 2011-12-28 2022-07-07 Kyoto Prefectural Public Univ Corp Normalización del cultivo de células endoteliales de la córnea
SG11201404943PA (en) 2012-02-15 2014-10-30 Ecole Polytech Erythrocyte-binding therapeutics
CN105658672A (zh) * 2013-08-22 2016-06-08 阿塞勒隆制药公司 TGF-β受体II型变体及其用途
RU2712967C2 (ru) 2013-10-31 2020-02-03 Киото Прифекчурал Паблик Юниверсити Корпорэйшн Терапевтическое средство против заболеваний, связанных с гибелью клеток эндотелия роговицы, обусловленной состоянием эндоплазматического ретикулума
CN105934249A (zh) * 2013-11-21 2016-09-07 布里格姆及妇女医院股份有限公司 用于治疗肺高压的组合物和方法
AR098827A1 (es) * 2013-12-19 2016-06-15 Consejo Nac De Investig Científicas Y Técnicas (Conicet) ISOFORMA DEL RECEPTOR II DE TGF-b, POLINUCLEÓTIDOS QUE LA CODIFICAN VECTORES, CÉLULAS TRANSFORMADAS, PÉPTIDOS Y DE FUSIÓN, MÉTODO Y USOS
PE20210168A1 (es) * 2014-02-10 2021-01-28 Merck Patent Gmbh INHIBICION DIRIGIDA DEL FACTOR DE CRECIMIENTO TRANSFORMADOR ß (TGFß)
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
AU2015233084B2 (en) 2014-02-21 2020-12-17 Anokion Sa Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
CN114470207B (zh) 2014-08-01 2023-09-19 布里格姆及妇女医院股份有限公司 与肺动脉高压的治疗有关的组合物和方法
US10882903B2 (en) 2015-05-18 2021-01-05 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for treating an alphavirus infection
CA2994413A1 (en) * 2015-08-04 2017-02-09 Acceleron Pharma, Inc. Methods for treating myeloproliferative disorders
US20200231652A1 (en) * 2015-08-31 2020-07-23 National Research Council Of Canada Tgf-b-receptor ectodomain fusion molecules and uses thereof
CA3025020A1 (en) * 2016-05-20 2017-11-23 President And Fellows Of Harvard College Gene therapy methods for age-related diseases and conditions
CA3038526A1 (en) * 2016-09-27 2018-04-05 Epicentrx, Inc. Immunomodulatory fusion proteins
KR20190129896A (ko) * 2017-03-02 2019-11-20 내셔날 리서치 카운실 오브 캐나다 Tgf-β-수용체 엑토도메인 융합 분자 및 그의 용도
KR102635723B1 (ko) * 2017-05-04 2024-02-08 악셀레론 파마 인코포레이티드 Tgf-베타 수용체 유형 ii 융합 단백질 및 이의 용도
WO2018232176A1 (en) 2017-06-16 2018-12-20 The University Of Chicago Compositions and methods for inducing immune tolerance
CN111511769B (zh) 2017-09-27 2024-05-24 埃皮辛特瑞柯斯公司 免疫调节性融合蛋白
KR20200130709A (ko) 2018-03-06 2020-11-19 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 전립선-특이 막 항원 car 및 이의 사용 방법
MX2020009394A (es) 2018-03-09 2021-01-15 Agenus Inc Anticuerpos anti-cd73 y métodos de uso de los mismos.
CN111867612A (zh) * 2018-03-26 2020-10-30 阿尔托生物科学有限责任公司 抗PDL1、IL-15和TGF-β受体组合分子
CN112672753A (zh) 2018-07-09 2021-04-16 普瑞赛格恩公司 融合构建体及其使用方法
JP2022527972A (ja) 2019-04-02 2022-06-07 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 前悪性病変を有する患者において癌を予測及び予防する方法
WO2021021528A1 (en) * 2019-07-26 2021-02-04 Board Of Trustees Of Michigan State University Methods of preventing or treating fatty degeneration of skeletal muscle
EP4021928A4 (en) * 2019-08-29 2023-09-20 NantBio, Inc. MODIFIED N-810 AND ASSOCIATED METHODS
EP4054617A4 (en) * 2019-11-05 2023-12-27 Acceleron Pharma Inc. TREATMENTS FOR SYSTEMIC SCLERosis
CN113968903A (zh) * 2020-07-24 2022-01-25 迈威(上海)生物科技股份有限公司 TGF-β RII突变体及其融合蛋白
WO2023141724A1 (en) 2022-01-28 2023-08-03 35Pharma Inc. Activin receptor type iib variants and uses thereof
WO2023206188A1 (en) * 2022-04-28 2023-11-02 Wenzhou Prarucom Bio-Chemical Technology Co. Method for alleviating pulmonary fibrosis using epidermal growth factor

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4874702A (en) * 1980-09-08 1989-10-17 Biogen, Inc. Vectors and methods for making such vectors and for expressive cloned genes
US4588585A (en) * 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4797368A (en) * 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US6129914A (en) * 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
DE69332026T2 (de) * 1992-10-29 2002-10-31 Celtrix Pharma Typ ii tgf-beta-bindendes rezeptorfragment als therapeutisches mittel
AU687790B2 (en) * 1993-02-09 1998-03-05 Biogen Idec Ma Inc. Treatment for insulin dependent diabetes
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease

Also Published As

Publication number Publication date
JP2008106076A (ja) 2008-05-08
IL132249A0 (en) 2001-03-19
EP0975771B1 (en) 2007-07-11
EA199900947A1 (ru) 2000-04-24
PT975771E (pt) 2007-10-01
KR20010006534A (ko) 2001-01-26
DE69838061D1 (de) 2007-08-23
AU737106B2 (en) 2001-08-09
NZ500284A (en) 2001-09-28
NO994998L (no) 1999-12-20
NO994998D0 (no) 1999-10-14
JP2001515360A (ja) 2001-09-18
WO1998048024A1 (en) 1998-10-29
CA2286933A1 (en) 1998-10-29
BR9808934A (pt) 2000-08-01
EP0975771A1 (en) 2000-02-02
ATE366816T1 (de) 2007-08-15
IS5217A (is) 1999-10-15
PL336306A1 (en) 2000-06-19
ES2289778T3 (es) 2008-02-01
DE69838061T2 (de) 2008-03-13
AU7120898A (en) 1998-11-13
US20050203022A1 (en) 2005-09-15
TR199902878T2 (xx) 2000-02-21
CN1257545A (zh) 2000-06-21
EE9900492A (et) 2000-06-15

Similar Documents

Publication Publication Date Title
DK0975771T3 (da) Fusionsproteiner af TGF-beta-receptortype II og immunoglobulins konstante region
FI20070170A (fi) Immunoglobuliinit, joista puuttuvat kevyet ketjut
DK0996728T3 (da) Forbedrede anti-IgE antistoffer og fremgangsmåde til forbedring af antistoffer
KR950700779A (ko) 단백질의 정제방법(Protein purification)
DE69536078D1 (de) Inhibitoren
CY2007012I2 (el) Αντισωματα anti-vegf
BR9507594B8 (pt) Anticorpo monoclonal com scfv humanizado, molécula de ácido nucleico recombinante e proteína recombinante.
DK0871631T3 (da) Antiparasitære marcfortiner og paraherquamider
DK0917879T3 (da) Forbedret fremgangsmåde til stabilisering af proteiner
DE69828154D1 (de) Anti-alphavbeta3 humanizierte monoklonale antikörper
PT1027339E (pt) Metodo e reagentes para a n-alquilacao de ureidos
DK0829579T3 (da) Farbart bindelag og fremgangsmåde til den fremstilling
CY1106887T1 (el) Πρωτεϊνες συντηξης τυπου ii tgf-b υποδοχεα/σταθερης περιοχης ανοσοσφαιρινης
BR1100555B1 (pt) anticorpos monoclonais humanizados.